TARX (Tarsier Pharma) Stock Based Compensation: $1.29 Mil (TTM As of Dec. 2025)


What is Tarsier Pharma Stock Based Compensation?

Tarsier Pharma TARX Stock Based Compensation is $1.29 Mil as of Dec. 2025.

Tarsier Pharma's Stock Based Compensation for the six months ended in Dec. 2025 was $0.92 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 was $1.29 Mil.

Tarsier Pharma Stock Based Compensation Related Terms

Tarsier Pharma Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Tarsier Pharma's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tarsier Pharma Stock Based Compensation Chart

Tarsier Pharma Annual Data
Trend Dec23 Dec24 Dec25
Stock Based Compensation
0.42 0.60 1.29

Tarsier Pharma Semi-Annual Data
Dec23 Jun24 Dec24 Jun25 Dec25
Stock Based Compensation 0.00 0.29 0.31 0.37 0.92

Tarsier Pharma Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $1.29 Mil.

What does a Stock Based Compensation of $1.29 Mil mean?
Tarsier Pharma (TARX) has a Stock Based Compensation of $1.29 Mil as of Dec. 2025. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Tarsier Pharma and its competitors.
Is Tarsier Pharma's Stock Based Compensation too high?
Tarsier Pharma's current Stock Based Compensation is $1.29 Mil.
How does Tarsier Pharma's Stock Based Compensation compare to ?
Tarsier Pharma's Stock Based Compensation of $1.29 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Tarsier Pharma and its competitors. Tarsier Pharma's current Stock Based Compensation is $1.29 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tarsier Pharma stock overvalued right now?
Tarsier Pharma (TARX) has a current Stock Based Compensation of $1.29 Mil. The current Stock Based Compensation is $1.29 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Tarsier Pharma (TARX), the current Stock Based Compensation is $1.29 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Tarsier Pharma Business Description

Comparable Companies
Tarsier Pharma Ltd is a late clinical stage biopharmaceutical company, focused on the development and commercialization of novel pharmaceutical therapies to address unmet needs in ocular diseases with underlying inflammatory pathologies. Its dazdotuftide platform technology is a bio-inspired immunomodulator designed to treat blinding inflammatory ocular diseases, and is currently being developed as both eye drops and intravitreal injections. The company's Product Candidate Pipeline includes TRS01 and TRS02.